← Back to Search

Imaging Agent

Near Infrared Imaging for Lung Cancer

Phase 1
Waitlist Available
Led By Yolonda L. Colson, MD, PhD
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights

Study Summary

This trial is testing if surgeons can find and remove the first lymph node that a tumor drains into. Doing this could help improve the ability to find and remove all tumor cells.

Eligible Conditions
  • Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To evaluate the safety and efficacy of near-infrared technology to guide therapeutic sentinel lymph node dissection in patients with lung cancer.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Near Infrared ImagingExperimental Treatment1 Intervention
The intervention to be administered is indocyanine green dye.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Near Infrared Imaging
2013
Completed Phase 1
~10

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor
1,083 Previous Clinical Trials
341,674 Total Patients Enrolled
Brigham and Women's HospitalOTHER
1,626 Previous Clinical Trials
11,473,565 Total Patients Enrolled
Beth Israel Deaconess Medical CenterOTHER
839 Previous Clinical Trials
13,011,412 Total Patients Enrolled

Media Library

Near Infrared Imaging (Imaging Agent) Clinical Trial Eligibility Overview. Trial Name: NCT00264602 — Phase 1
Lung Cancer Research Study Groups: Near Infrared Imaging
Lung Cancer Clinical Trial 2023: Near Infrared Imaging Highlights & Side Effects. Trial Name: NCT00264602 — Phase 1
Near Infrared Imaging (Imaging Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00264602 — Phase 1
~3 spots leftby Jun 2025